Quick Shot #11 Answer
Answer: Ustekinumab and Adalimumab
Ustekinumab and adalimumab were recently studied head-to-head as first line therapy for moderate-to-severe Crohn’s disease (SEAVUE trial). The primary endpoint of clinical remission (CDAI < 150) at week 52 was met in 61% of subjects receiving adalimumab and 64.9% of subjects receiving ustekinumab, which was not a statistically significant difference. Vedolizumab and adalimumab were studied head-to-head for ulcerative colitis in the VARSITY trial. Comparisons of efficacy of other biologic agents has been derived from systematic reviews and network meta-analyses, but not from randomized head-to-head trials.
- Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV Jr, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ; SEAVUE Study Group. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2. PMID: 35691323.
- Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. PMID: 31553834.